News

News Jul 19, 2014 CardioCell launches trial to assess stem cell therapy for chronic HF CardioCell announced the initiation of a phase 2a trial of ischemia-tolerant mesenchymal stem cell therapy for patients with chronic HF due to nonischemic cardiomyopathy. READ FULL ARTICLE

News Jul 15, 2014 Stem Cell Therapy in Cardiovascular Disease: Past Obstacles and Promising New Directions CardioCell's Scientific Advisory Board Chair Dr. Stephen E. Epstein shares insights on why, after a string of failures, researchers are coming back from the drawing board with

News Jul 14, 2014 CardioCell Begins Phase 2A Trial Of itMSC In HF Stemedica Cell Technologies subsidiary CardioCell announced that it has initiated its Phase IIA clinical trial investigating its proprietary ischemia-tolerant mesenchymal stem cells (itMSCs) in patients with chronic

Stemedica’s CardioCell LLC subsidiary began a single-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 1.5 million cells/kg IV itMSCs in about 20 CHF patients with non-ischemic cardiomyopathy. SUBSCRIPTION REQUIRED TO READ FULL ARTICLE

News Jul 10, 2014 CardioCell begins phase IIa trial using itMSC therapy for chronic heart failure CardioCell, a Stemedica Cell Technologies subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, has started its phase IIa clinical trial for chronic

News Jul 9, 2014 Tests Advance for CardioCell Medicine   CardioCell, a stem cell company in San Diego, has started a Phase 2a clinical trial of its treatment for chronic heart failure. The company’s special stem cells are injected into patients with heart failure not caused

News Jul 8, 2014 CardioCell Launches Phase 2a Chronic Heart Failure Trial  CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, started its Phase 2a clinical trial for chronic heart failure (HF)